VIMU Therapeutics, LLC was founded in 2021 by Drs. Shashidharamurthy Taval, Vicky Mody, and Srujana Rayalam who bring more than 15 years of experience in exploring new therapeutic options for inflammatory and infectious diseases. The founders have been faculty members at PCOM for more than a decade.
The team has developed a novel combinatorial approach to inhibit SARS-CoV-2 viral replication. This approach reduces drug toxicity and enhances safety by using small molecular
weight compounds that inhibit key viral enzymes, including 3CLpro, PLpro, and RdRp;
critical drug targets for COVID-19 treatment.
VIMU Therapeutics intellectual property (PCT/US2023/011690) covers compositions and methods for preventing and treating viral infections, particularly coronaviruses like SARS-CoV-2, as well as a combinatorial approach of using 3CLpro, PLpro, and/or RdRp inhibitors to combat COVID-19.
VIMU Therapeutics aims to become a leader in developing potent small molecule compounds that inhibit SARS-CoV-2 replication, prevent cytokine storm, and offer a safer profile compared to existing COVID-19 treatments. The company also plans to apply similar strategies to develop therapies for other viral and parasitic infections.
© 2025 Philadelphia College of Osteopathic Medicine